Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. (17th January 2020)

• Record Type: Journal Article
• Authors: Li, Chenggong; Mei, Heng; Hu, Yu
• Is Part Of: Briefings in functional genomics. Volume 19:Number 3(2020)
• Page Start: 175
• Page End: 182
• Publication Date: 2020-01-17
• Subjects: CAR T cells -- CRISPR -- Cas9 -- cancer immunotherapy -- genome editing; Genomics -- Methodology -- Periodicals; Genomics -- Technological innovations -- Periodicals; 572.86072
• DOI: 10.1093/bfgp/elz042
• Languages: English
• ISSNs: 2041-2649

Abstract

Abstract: Chimeric antigen receptor(CAR) T-cell therapy has shown remarkable effects and promising prospects in patients with refractory or relapsed malignancies, pending further progress in the next-generation CAR T cells with more optimized structure, enhanced efficacy and reduced toxicities. The clustered regulatory interspaced short palindromic repeat/CRISPR-associated protein 9 (CRISPR/Cas9) technology holds immense promise for advancing the field owing to its flexibility, simplicity, high efficiency and multiplexing in precise genome editing. Herein, we review the applications and explorations of CRISPR/Cas9 technology in constructing allogenic universal CAR T cells, disrupting inhibitory signaling to enhance potency and exploration of safer and more controllable novel CAR T cells.